Hodgkin Lymphoma Clinical Trials: Monitor cHL and NLPHL Programs Daily

Why Hodgkin lymphoma trial monitoring matters

Classical Hodgkin lymphoma (cHL) is one of the most curable cancers in oncology — approximately 80–90% of newly diagnosed patients achieve long-term remission with first-line ABVD or BV-AVD chemotherapy. Yet despite that excellent overall prognosis, relapsed and refractory disease represents a durable commercial and scientific opportunity. Roughly 15–20% of patients relapse after first-line therapy or are refractory to it, and these patients face a challenging treatment landscape that has driven significant development activity over the past decade.

Brentuximab vedotin (BV), Seagen's CD30-targeting ADC, reshaped Hodgkin lymphoma treatment after its approval in relapsed/refractory disease in 2011 and subsequently moved into frontline combinations. The ECHELON-1 trial established BV-AVD as a standard first-line option for advanced-stage cHL, demonstrating improvement in progression-free survival over ABVD. Simultaneously, checkpoint inhibitor monotherapy — pembrolizumab (KEYNOTE-087) and nivolumab (CheckMate 205) — demonstrated striking response rates in heavily pretreated relapsed/refractory cHL, reflecting the disease's unique biology: cHL tumor cells (Reed-Sternberg cells) amplify the PD-L1/PD-L2 loci and create a strongly immunosuppressive tumor microenvironment that is exquisitely sensitive to PD-1 blockade.

The current development frontier in cHL involves combining BV with checkpoint inhibitors — the "BV plus nivolumab" and "BV plus pembrolizumab" regimens have shown high complete response rates in relapsed/refractory cHL as bridges to autologous stem cell transplant (ASCT), and are being tested as ASCT-sparing frontline approaches in select patient populations. The question of whether post-ASCT consolidation with BV or checkpoint inhibitors can further improve long-term outcomes is driving multiple ongoing Phase 2 and 3 trials.

Cellular therapies are entering the Hodgkin lymphoma space later than other lymphomas — largely because the tumor microenvironment that makes cHL sensitive to checkpoint inhibitors also creates challenges for CAR-T approaches. Nevertheless, CD30-targeted CAR-T programs are in Phase 1/2 development and generating early signals that are attracting close attention from hematology sponsors.

Key signals that hematology competitive intelligence professionals track in Hodgkin lymphoma:

• BV + checkpoint inhibitor combination trials — both as first-line ASCT-sparing and relapsed/refractory regimens
• CD30-targeted CAR-T and CAR-NK programs entering Phase 1 dose escalation
• Novel ADC programs targeting CD30 or alternative cHL surface antigens with differentiated payload or linker strategies
• Post-ASCT consolidation and maintenance trials with checkpoint inhibitors or BV
• NLPHL-specific trials — a distinct histology with CD20 expression and different biology that represents a smaller but distinct opportunity

What DataLookout monitors for Hodgkin lymphoma

DataLookout pulls directly from the ClinicalTrials.gov API every day. For a Hodgkin lymphoma watch profile, you can configure:

• Condition keywords: "Hodgkin lymphoma", "Hodgkin's disease", "classical Hodgkin lymphoma", "cHL", "NLPHL", "nodular lymphocyte predominant Hodgkin lymphoma", "CD30", "Reed-Sternberg"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors (including NIH and academic)
• Status filter: Recruiting only, all active studies, or any status including completed/terminated

Because Hodgkin lymphoma is relatively rare, most users configure broad profiles covering all phases and both industry and academic sponsors to ensure comprehensive coverage of the full landscape. The free plan's single profile is often sufficient for this indication.

How it compares to ClinicalTrials.gov RSS alerts

ClinicalTrials.gov does have a basic RSS/email notification system, but it has significant limitations for professional use:

• No phase filtering — you get every Phase 1 first-in-human study alongside major Phase 3 trials
• No sponsor type filtering — academic, NIH, and industry trials are mixed together
• No clear labeling of "new" vs. "updated" trials — everything looks the same
• No support for multiple simultaneous search profiles
• Difficult to set up and manage for non-technical users

DataLookout delivers filtered, labeled, and organized alerts — the intelligence layer on top of the raw data.

Who uses Hodgkin lymphoma trial monitoring

Competitive intelligence teams at hematology-oncology companies

Companies with approved or pipeline assets in CD30-targeting, checkpoint inhibition, or cellular therapies for lymphomas maintain active CI coverage of the Hodgkin lymphoma trial landscape. Given the relatively small number of annual new diagnoses (~9,000/year in the U.S.), Hodgkin lymphoma is a niche indication where individual trial results can materially shift treatment patterns. CI teams tracking BV combination strategies — particularly BV plus nivolumab or pembrolizumab in the first-line setting — need to know quickly when competitors open new trials or when academic groups post investigator-initiated studies testing those combinations. DataLookout surfaces these updates the morning after they appear on ClinicalTrials.gov.

Business development teams evaluating lymphoma assets

BD teams at large and mid-size pharma companies use Hodgkin lymphoma trial monitoring to identify promising cellular therapy and novel ADC programs from smaller biotechs before they generate headline Phase 2 data. CD30-targeted CAR-T is a particularly active early sourcing space, as Phase 1 programs with preliminary response data in relapsed/refractory cHL are credible in-licensing candidates for companies with hematology-oncology franchises. Early-stage trial monitoring enables BD teams to initiate conversations before these assets generate wide market visibility.

Academic medical centers and cooperative group research teams

NCI-sponsored cooperative groups — SWOG, Alliance, ECOG-ACRIN — run a meaningful portion of the Hodgkin lymphoma trial landscape, particularly for questions that industry programs don't address: ASCT-sparing approaches in favorable-risk patients, late-effects optimization in adolescent and young adult populations, and second-line regimens for patients ineligible for autologous transplant. Research teams at academic medical centers use DataLookout to monitor when new cooperative group or industry trials open at sites near them, and to stay current on the full landscape when writing grant applications or designing investigator-initiated studies.

Frequently asked questions

How current is the Hodgkin lymphoma trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I monitor both cHL and NLPHL in the same profile?

Yes — your keyword profile can include both "classical Hodgkin lymphoma" and "nodular lymphocyte predominant Hodgkin lymphoma" (or "NLPHL") to capture both subtypes in a single daily digest. Alternatively, because NLPHL has distinct biology and a separate treatment approach (CD20-targeting with rituximab plays a larger role), some users prefer to create two separate profiles — one for cHL and one for NLPHL — to keep the alerts distinct. Multiple profiles are supported on the Starter ($49/month) and Pro ($149/month) plans.

Does DataLookout cover international trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — international trials registered on ClinicalTrials.gov are included. This covers most major industry-sponsored programs worldwide. European cooperative group trials (GHSG, LYSA) and global industry trials with U.S. sites are all captured in the daily feed.